University of Florida Completes Purchase of Cyntellect, Inc. LEAP(TM) System

SAN DIEGO, March 12 /PRNewswire/ -- Cyntellect, Inc., a privately-held biotechnology company, today announced that the University of Florida ("UF") has completed the purchase and installation of Cyntellect's Laser-Enabled Analysis and Processing ("LEAP") system. UF plans to exploit LEAP's in situ live cell manipulation capabilities to enable new approaches to functionally cloning cells & purifying valuable cell populations, as well as its laser-based delivery of molecules to important cell types for research in regenerative medicine and drug discovery.

LEAP is an automated live cell analysis and processing system that combines high-speed optical imaging (brightfield or fluorescence) and real-time image analysis with high-speed in situ laser manipulation of cells. Using LEAP, researchers have demonstrated: (i) accelerated functional cloning of cells, including highly-secreting cells for biopharmaceutical manufacturing purposes, (ii) image-based cell purification of adherent and non-adherent cell types and (iii) laser-based macromolecule delivery into cells, including siRNA, small molecules, proteins and quantum dots.

"We are proud to have LEAP technology selected by the University of Florida, one of the premier institutions conducting regenerative medicine research," stated Dr. Fred Koller, Cyntellect's President and CEO. "Their scientists immediately recognized the truly unique live cell processing capabilities that LEAP offers. As a result, we anticipate LEAP becoming a keystone technology for their expanding efforts in regenerative medicine."

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at http://www.cyntellect.com.

CONTACT: Jim Linton, Ph.D., Chief Business Officer of Cyntellect,
+1-858-382-7678, jlinton@cyntellect.com

Web site: http://www.cyntellect.com/

Back to news